CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma

Clinical Cancer Research

Volumn 18, Issue 19, 2012, Pages 5352-5363

  Rivera, Zeyana ^a,b   Ferrone, Soldano ^d   Wang, Xinhui ^d   Jube, Sandro ^a   Yang, Haining ^a,c   Pass, Harvey I ^e   Kanodia, Shreya ^a   Gaudino, Giovanni ^a   Carbone, Michele ^a,c  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULPHATE PROTEOGLYCAN 4; CYCLIN D1; FOCAL ADHESION KINASE; LUCIFERASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TP41.2; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; SIGNAL TRANSDUCTION; SURVIVAL RATE; TOXICITY TESTING; WOUND HEALING;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHONDROITIN SULFATE PROTEOGLYCANS; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MEMBRANE PROTEINS; MESOTHELIOMA; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84866931227     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0628     Document Type: Article

References (39)

1. Carbone M, Emri S, Dogan AU, Steele I, Tuncer M, Pass HI, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 2007;7:147-54. (Pubitemid 46160990)
2. Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 2012;227:44-58.
3. Qi F, Carbone M, Yang H, Gaudino G. Simian virus 40 transformation, malignant mesothelioma and brain tumors. Expert Rev Respir Med 2011;5:683-97.
4. Carbone M, Baris YI, Bertino P, Brass B, Comertpay S, Dogan AU, et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci U S A 2011;108:13618-23.
5. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43:1022-5.
6. Pass HI, Vogelzang N, Hahn SM, Carbone M. Benign and malignant mesothelioma. In:De Vita VT, Hellmann S, Rosemberg SA, editors. Cancer, principles & practice of oncology. 9th ed. Philadelphia: Lippincott Williams & Wilkins, a Wolters Kluwer business; 2011. p. 2052-80.
7. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008;5:136-47.
8. Campoli M, Ferris R, Ferrone S, Wang X. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res 2010;16:11-20.
9. Wilson BS, Imai K, Natali PG, Ferrone S. Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer 1981;28:293-300. (Pubitemid 11055996)
10. Chang CC, Campoli M, Luo W, Zhao W, Zaenker KS, Ferrone S. Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of nonimmunological mechanisms. Ann N Y Acad Sci 2004;1028:340-50. (Pubitemid 40361835)
11. Tillet E, Gential B, Garrone R, Stallcup WB. NG2 proteoglycan mediates beta1 integrin-independent cell adhesion and spreading on collagen VI. J Cell Biochem 2002;86:726-36. (Pubitemid 34839974)
12. de Vries JE, Keizer GD, te Velde AA, Voordouw A, Ruiter D, Rumke P, et al. Characterization of melanoma-associated surface antigens involved in the adhesion and motility of human melanoma cells. Int J Cancer 1986;38:465-73. (Pubitemid 16006915)
13. Burg MA, Tillet E, Timpl R, Stallcup WB. Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules. J Biol Chem 1996;271:26110-6. (Pubitemid 26347453)
14. Eisenmann KM, McCarthy JB, Simpson MA, Keely PJ, Guan JL, Tachibana K, et al. Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol 1999;1:507-13. (Pubitemid 129503671)
15. Yang J, Price MA, Neudauer CL, Wilson C, Ferrone S, Xia H, et al. Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol 2004;165: 881-91. (Pubitemid 38821978)
16. Klominek J, Sumitran Karuppan S, Hauzenberger D. Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of beta1 integrins. Int J Cancer 1997;72:1034-44. (Pubitemid 27433570)
17. Hafner C, Breiteneder H, Ferrone S, Thallinger C, Wagner S, Schmidt WM, et al. Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer 2005;114:426-32. (Pubitemid 40279964)
18. Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, et al. CSPG4 in cancer: multiple roles. Curr Mol Med 2010;10:419-29.
19. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43:1018-21.
20. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 2004;24:267-96. (Pubitemid 40052428)
21. Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD, Fetsch PA, et al. Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 1995;59:835-44.
22. Reale FR, Grif fin TW, Compton JM, Graham S, Townes PL, Bogden A. Characterization of a human malignant mesothelioma cell line (H-MESO- 1): a biphasic solid and ascitic tumor model. Cancer Res 1987;47:3199-205. (Pubitemid 17082649)
23. Smythe WR, Kaiser LR, Hwang HC, Amin KM, Pilewski JM, Eck SJ, et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 1994;57: 1395-401. (Pubitemid 24216301)
24. Bocchetta M, Di Resta I, Powers A, Fresco R, Tosolini A, Testa JR, et al. Human mesothelial cells are unusually susceptible to simian virus 40- mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci U S A 2000;97:10214-9.
25. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB- dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A 2006;103:10397-402. (Pubitemid 44051178)
26. Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, et al. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst 2010;102:1496-512.
27. Nasu M, Carbone M, Gaudino G, Ly BH, Bertino P, Shimizu D, et al. Ranpirnase interferes with NF-kappaB pathway and MMP9 activity, inhibiting malignant mesothelioma cell invasiveness and xenograft growth. Genes Cancer 2011;2:576-84.
28. Zhang L, Qi F, Gaudino G, Strianese O, Yang H, Morris P, et al. Tissue tropism of SV40 transformation ofhuman cells: role of the viral regulatory region and of cellular oncogenes. Genes Cancer 2010;1:1008-20.
29. Iida J, Skubitz AP, Furcht LT, Wayner EA, McCarthy JB. Coordinate role for cell surface chondroitin sulfate proteoglycan and alpha 4 beta 1 integrin in mediating melanoma cell adhesion to fibronectin. J Cell Biol 1992;118:431-44.
30. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
31. Iida J, Wilhelmson KL, Ng J, Lee P, Morrison C, Tam E, et al. Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A). Biochem J 2007;403:553-63. (Pubitemid 46706984)
32. Jube S, Rivera Z, Bianchi ME, Powers A, Wang E, Pagano IS, et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012;72:3290-301.
33. Iida J, Meijne AM, Spiro RC, Roos E, Furcht LT, McCarthy JB. Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and alpha 4 beta 1 integrin. Cancer Res 1995;55:2177-85.
34. Cheng GZ, Park S, Shu S, He L, Kong W, Zhang W, et al. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets 2008;8:2-6. (Pubitemid 351237904)
35. Yang J, Price MA, Li GY, Bar-Eli M, Salgia R, Jagedeeswaran R, et al. Melanoma proteoglycan modi fies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res 2009;69:7538-47.
36. Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 2008;68:8066-75.
37. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26:60-70. (Pubitemid 29411434)
38. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002;416:279-80. (Pubitemid 34260234)
39. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-49. (Pubitemid 38771819)